The ethchlorvynol (Placidyl, Abbott) was supplied by Abbott Laboratories, North Chicago, Ill.
The value of sedation, with and without psychotherapy, in the management of skin disorders is well recognized. Up to the present time, available drugs have been limited very largely to the barbiturates, but long-term treatment with these compounds may raise questions relating to habituation or even addiction. They may also cause toxic dermatological effects. For these reasons it was decided to evaluate the effects of ethchlorvynol (Placidyl) a new, nonbarbiturate sedative, as an aid in the management of skin disorders.
No particular method of selection was used. The patients were those considered likely to benefit from sedation. Appropriate local treatment for the skin condition was used in every case. All the patients were adult, and there was no special preponderance of any age group or either sex. Often the skin condition improved
SCHWARTZ FR. Ethchlorvynol (Placidyl) as a Sedative in Dermatological Practice. AMA Arch Derm. 1957;75(5):747–748. doi:10.1001/archderm.1957.01550170115022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: